MicroRNAs (miRNAs) are a class of small non-coding regulatory RNAs, and changes in miRNAs are involved in tumor origin and progression. Studies have shown that miR-20a is overexpressed in human ovarian cancer tissues and that this miRNA enhances long-term cellular proliferation and invasion capabilities. In this study, a positive correlation between serum miR-20a expression and ovarian cancer stage was observed. We found that miR-20a binds directly to the 39-untranslated region of MICA/B mRNA, resulting in its degradation and reducing its protein levels on the plasma membrane. Reduction of membrane-bound MICA/B proteins, which are ligands of the natural killer group 2 member D (NKG2D) receptor found on natural killer (NK) cells, cd 1 T cells and CD8 1 T cells, allows tumor cells to evade immune-mediated killing. Notably, antagonizing miR-20a action enhanced the NKG2D-mediated killing of tumor cells in both in vitro and in vivo models of tumors. Taken together, our data indicate that increased levels of miR-20a in tumor cells may indirectly suppress NK cell cytotoxicity by downregulating MICA/B expression. These data provide a potential link between metastasis capability and immune escape of tumor cells from NK cells.
INTRODUCTION
MHC class I chain-related molecules A and B (MICA and MICB, together referred to as MICA/B) are widely expressed on epithelial tumor cells and are recognized by cd 1 T cells, CD8
1 T cells and natural killer (NK) cells by the NK group 2 member D (NKG2D) receptor. The NKG2D-MICA/B pathway plays a major role in immune surveillance to identify malignant cells. [1] [2] [3] The MICA/B ligands and their activating receptor NKG2D play an important role in NK, cd 1 and CD8 1 T-cell-mediated immune responses to tumors. 4, 5 These ligands are typically induced by tumor-associated antigen 6 and the hypoxic stress commonly associated with cancer. 7 However, cancer cells are able to reduce the levels of these surface ligands by inducing their downregulation and/or internalization 8 and by causing them to shed their extracellular domains, thus preventing detection by immune cells. 9, 10 Recently, MICA/B mRNA has been detected in normal healthy human tissues 11, 12 and in adult and normal embryonic mice. 12 This finding indicates that certain post-transcriptional mechanisms may exist to prevent the translation of these mRNAs in healthy individuals, presumably to avoid autoimmunity. MicroRNAs (miRNAs) are a cluster of small non-coding RNAs that are approximately 22 nucleotides in size. miRNAs post-transcriptionally regulate target mRNA expression by recognizing complementary sites within the 39-untranslated region (UTR) of the target mRNA, thus stimulating cell-autonomous degradation of the target mRNA. 13, 14 Increasing evidence indicates that miRNAs are frequently altered in cancers and are therefore believed to play important roles in tumor formation and development. Extensive efforts have been devoted to studying the clinical significance of miRNAs in clinical samples, such as serum, as potential diagnostic biomarkers of cancer. Previous studies have shown that miR-20a is upregulated in severe ovarian carcinomas compared with normal ovarian tissues and that miR-20a expression levels correlate with survival in patients with severe ovarian carcinomas. 15, 16 These data led us to question whether miR-20a contributes to the post-transcriptional regulation of MICA/B expression and the immune escape of ovarian carcinoma cells.
In this study, we found a positive correlation between the level of serum miR-20a and the stage of ovarian cancer. Next, we studied the effect of miR-20a on the regulation of MICA/B expression using the ovarian cancer cell line SKOV3. We determined that miR-20a inhibited the expression MICA/B by interacting with the 39-UTR of MICA/B. We further showed that overexpression of miR-20a inhibited MICA/B expression and NK cytotoxicity in vivo. Taken together, the data presented in this study further our understanding of how miR-20a expression might modulate the molecular mechanisms underlying ovarian cancer immune escape.
MATERIALS AND METHODS
Clinical sample collection and RNA extraction Serum from 34 ovarian cancer patients, 10 ovarian cysts and 20 age-and gender-matched healthy volunteers were obtained from the Department of Gynecology at the Affiliated Nanjing Hospital of Nanjing Medical University. The serum samples were collected prior to any therapeutic treatment. All studies involving human participants were approved by the Ethics Committee of Nanjing Medical University, and written informed consent was obtained from all donors. The blood samples were centrifuged at 1500g for 10 min at 4 uC to completely remove the remaining cells. The serum samples were collected gently and stored at 280 uC until further use.
Isolation of RNA and quantification of the miR-20a levels in serum and ascites were performed as described previously. 17 Total RNA was isolated from each serum sample using Trizol LS Reagent (Invitrogen, California, USA) according to the manufacturer's instructions. Briefly, 200 ml of serum or ascites was mixed with 200 ml of diethylpyrocarbonate-treated water, 200 mL of phenol and 200 ml of chloroform. The mixture was then centrifuged at 12 000g for 15 min at 25 uC, and the upper aqueous layer was collected. Next, 40 ml of 3 M sodium acetate and 800 ml of isopropyl alcohol were added to the aqueous layer. The solution was then incubated at 220 uC for 1.5 h, after which it was centrifuged at 15 000g for 15 min at 4 uC. The RNA pellet was then washed once with 1 ml of 75% ethanol and dried at 37 uC. Finally, the RNA pellet was dissolved in 20 ml of diethylpyrocarbonate-treated H 2 O and stored at 280 uC until further use.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of miRNAs The initial miRNA analysis was performed using arrays. Briefly, the sample utilized for the TaqMan Low-Density Array profiling assay (Applied Biosystems, California, USA) consisted of serum pooled from 34 ovarian cancer patients, 10 ovarian cysts or 20 healthy volunteers. The serum miRNA expression was profiled using TaqMan Human miRNA Arrays following the manufacturer's recommended protocol. The expression levels of 667 miRNAs were analyzed together with endogenous control genes and negative controls using this profiling platform, which consists of three 384-well microfluidic cards. First, 20 ng of RNA was reverse transcribed to obtain cDNA with the TaqMan miRNA reverse transcription kit using a GeneAmp PCR System 9700. For real-time PCR analysis, amplification was performed with the TaqMan miRNA multiplex RT assays according to the manufacturer's instructions. The data were analyzed using Sequence Detection Systems Relative Quantification Software. According to the geNorm pairwise variation (V) value, miR16 and miR19b were most similar to the mean of the TaqMan LowDensity Array and were therefore selected as endogenous controls. The miR-20a level in each serum sample was assessed using the One Step PrimeScript miRNA cDNA Synthesis Kit (Dalian, China). Quantitative RT-PCR was performed in duplicate, and the mean was calculated. We utilized the averages of miR16 and miR19b as internal controls for miRNA analysis of serum. The miR-20a expression level in serum was calculated using the following equation:
18 DC TmiR20a 5C TmiR20a 2(C tmiR16 1C tmiR19b )/2.
Cell lines and transfection
The human ovarian cancer cell lines SKOV3 and ES-2 were obtained from the Institute of Biochemistry and Cell Biology (Shanghai, China). The NK-92 cell line (human NK cell line) was provided by Professor Haiming Wei (University of Science and Technology of China) and was originally purchased from the American Type Culture Collection. The SKOV3, ES-2, and K562 cells were grown in RPMI 1640 medium (Gibco BRL, New York, USA) supplemented with 10% fetal bovine serum, 100 mg/ml streptomycin and 100 mg/ml penicillin. NK-92 cells were grown in alpha minimum essential medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 100 U/ml recombinant human IL-2. The cells were transfected with miR-20a and anti-miR20a mimics (GenePharma, Shanghai, China); RNA oligos (GenePharma) were utilized as controls. Transient transfection was performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. The media were replaced after 24 h of transfection. The cells were harvested in phosphate-buffered saline (PBS) at 96 h post-transfection and then subjected to RT-PCR and flow cytometry (FCM) analysis using an anti-MICA/B-PE antibody (Clone # 6D4; BD PharMingen, San Diego, USA).
DNA constructs and luciferase assay
Luciferase reporters were generated by inserting the wild-type or mutated 39-UTR of MICA/B at the 39 end of the open reading frame region in the pGL3 luciferase reporter vector (Promega Corp., Madison, WI, USA). 19 The orientation of the inserts was confirmed by sequencing. The SKOV3 and ES-2 cells were transfected with the pGL3 control vector or the PGL3 reconstructed vector containing either the wild type or mutant 39-UTR in combination with 40 nM miR-20a mimics and 20 ng of the pGL-Renilla luciferase vector as a transfection control. We used 40 nM RNA oligos (Qiagen, Düsseldorf, Germany) as a negative control. The Reporter Assay System Kit (Promega) was used to measure the luciferase activity 48 h after transfection according to the manufacturer's instructions.
NK cytotoxicity assay
The NK-92 cell-mediated cytotoxicity against the ovarian cancer cells modified with miR-20a was measured as described previously. 20 In brief, the SKOV3 target cells transfected with miR-20a, anti-miR-20a mimics and RNA oligo controls were labeled with 5.0 mM carboxyfluorescein diacetate succinimidyl ester (CFSE) in 5% CO 2 for 10 min at 37 uC. The stained cells were washed twice with phosphate-buffered saline and subsequently resuspended in complete RPMI 1640 medium. A target ratio of 20 : 1 was used. The stained cells and NK-92 cells were mixed with complete medium and incubated in a 96-well plate (200 ml/well) at 37 uC with 5% CO 2 for 4 h. The PI apoptosis kit was used to determine the percentage of stained (apoptotic) cells by flow cytometry.
Lung clearance assay
To evaluate the miR-20a-mediated immune effect in vivo, the in vivo lung clearance assay was used as previously described 21 with some modifications. Briefly, 30 male C57B/6 mice (9-10 weeks old) were divided into three groups and were intraperitoneally injected with either an anti-mouse NKG2D monoclonal antibody (mAb) (Clone # C7; Novus, Missouri, USA) at a concentration of 300 mg per mouse or an isotype IgG control. Twenty-four hours later, HeLa cells (negative control cells that are not efficiently killed by mouse NK cells) were labeled with the fluorescent dye Vybrant DiD (Invitrogen), and the various SKOV3 cells (transfected with miR-20a, anti-miR-20a sponge or a control miRNA) were labeled with CFSE (Invitrogen). The stained SKOV3 cells were mixed with the stained HeLa cells of each population at a density of 5310 6 cells in 1 ml of phosphate-buffered saline, and a 0.4-ml aliquot of the cells was implanted via the tail vein. The lungs were isolated 5 h later to prepare the single-cell suspensions by employing cell strainers, and fluorescence-activated cell sorting was performed. The mean fluorescence intensity ratio of the stained cells to the HeLa cells was then calculated. The ratio of the SKOV3 cells transfected with control miRNA to the HeLa cells in the group treated with anti-NKG2D IgG was set as 100%.
Statistical analysis
Statistical significance was assessed using one-way analysis of variance and the Bonferroni post-hoc test with SPSS 12.0 software. Survival probabilities (5-year overall survival) were analyzed using the Kaplan-Meier product limit method. The log-rank test was used to analyze the differences between the groups. P values ,0.05 were considered statistically significant.
RESULTS
Increased expression of miR-20a in the serum of ovarian cancer patients is correlated with disease progression. Previous studies employing miRNA microarrays revealed that miR-200a, miR-141, miR-16, miR-200b, miR-200c and miR20a levels are increased (more than twofold), whereas miR-100 levels are lower in ovarian cancer patients than in with healthy controls. 15, 16 Among these miRNAs, miR-20a in particular has been reported to regulate T-cell activation genes in both knock-in and knock-down T-cell models. 22 To investigate the expression of miR-20a in ovarian cancer patients and to determine the correlation between miR-20a levels and disease severity, we further explored the role of miR-20a in serum specimens from patients with epithelial ovarian cancer.
Serum miR-20a expression was assessed by qRT-PCR in patients with ovarian tumors (n534), patients with ovarian cysts (n510) and healthy controls (n520). As shown in Table 1 , the DC TmiR20a was significantly lower in the patients than in the normal controls (P,0.05), whereas DC TmiR20a in the serum of patients with ovarian cyst disease appeared normal, thus indicating that miR-20a levels were significantly higher in ovarian cancer patients than in both normal controls and ovarian cyst disease controls. To evaluate the association between miR-20a and the clinicopathological features of ovarian cancer, we analyzed miR-20a levels in the sera of patients with ovarian cancers classified by metastasis or the International Federation of Gynecology and Obstetrics (FIGO) disease stage. The miR-20a expression level was significantly increased in the patients with metastasis and stage III-IV disease (P,0.05). There was no correlation between miR-20a expression and other tumor characteristics (Table 1) . These results indicate that miR20a may be associated with the progression of ovarian cancer.
miR-20a expression and ovarian cancer prognosis
To determine whether miR-20a is associated with the prognosis of ovarian cancer patients, the median value (DC T 51.55) of the relative serum miR-20a expression of all patients was used to define the high-and low-expression groups (n515 and 19, Figure 3a and b). These vectors were transfected into SKOV3 cells that were also transfected with miR-20a (40 and 80 nM) or control (non-targeting) RNA oligos. A significant decrease in the luciferase activity of MICA and MICB was observed in the presence of miR-20a, whereas the mutations in the MICA and MICB 39-UTRs abolished this effect (Figure 3c ). This result indicates that miR-20a directly targets MICA/B at the predicted binding site.
Downregulation of MICA/B by miR-20a reduces NKG2D-mediated killing Next, we investigated whether miR-20a-mediated downregulation of MICA/B affects biological functions in vitro. SKOV3 target cells were transfected with miR-20a, anti-miR-20a mimics or control RNA oligos. Next, we pre-labeled the transfected SKOV3 cells with CFSE and evaluated the role of miR-20a in NK cytotoxicity assays, which were performed by coculturing SKOV3 cells with NK cells. As shown in Figure 4 , transfection with miR-20a resulted in a moderate decrease in the cytolytic activity of the NK92 cells at various effector-to-target ratios. In addition, anti-miR-20a reversed these inhibitory effects. Taken together, these results indicate that the miR-20a-mediated decrease in MICA/B expression reduced killing by NK cells.
miR-20a mediated immune evasion in vivo
Despite the fact that human MICA/B are different from those of the mouse, immunocompetent mice can eliminate human malignant cells via the NKG2D-MICA/B pathway. 21 Mice treated with a blocking anti-NKG2D mAb (to deplete NKG2D 1 immune cells) were used to investigate miR-20a-mediated immune effects in vivo. 
DISCUSSION
The activating receptor NKG2D and its ligands play important roles in NK, cd 1 and CD8 1 T cell-mediated immune responses to tumors. 14, 17 However, tumors have developed various mechanisms to escape immune cell-mediated elimination, thus allowing tumor relapse. 24 Recent studies have found that tumor cells abnormally express a number of miRNAs, and this abnormal miRNA expression profile significantly contributes to tumor immune escape. 25 Previous studies have reported that miR-20a is not only related to tumor development 26, 27 but also associated with invasive activity in ovarian carcinoma cells. 28 In this study, we investigated the role of miR-20a and its posttranscriptional regulation of MICA/B in ovarian carcinoma.
Although previous studies have revealed that miR-20a is highly expressed in ovarian cancer, these studies mainly focused on miR-20a expression in tissues. Our study confirms that miR-20a expression is not only significantly higher in ovarian cancer patients than in normal controls but also significantly associated with metastasis and poor prognosis of ovarian cancer. miRNAs in serum, which are mostly derived from cells with a damaged plasma membrane, 29 circulate in the blood in a cell-free and relatively stable form 30 and are regarded as a promising new class of biomarkers. 31 However, further clinical studies are warranted to fully evaluate the diagnostic potential of serum miR-20a in ovarian cancer in specific prospective studies. In this study, we report that miR-20a expression is significantly enhanced in ovarian cancer patients with CA-125 f500 U/ml but not in those with CA-125 .500 U/ml, which may be caused by individual variations. However, further clinical studies are warranted to fully evaluate the relationship of CA-125 and serum miR-20a in ovarian cancer. Because miR-20a levels are correlated with disease metastasis, we hypothesized that this association might be due to the miR-20a-mediated downregulation of MICA/B mRNA. To test this possibility, SKOV3 and ES-2 cells were transfected with miR-20a to determine the effect of miR-20a expression on MICA/B levels. RT-PCR and FCM analyses indicated that miR-20a reduced the levels of MICA/B mRNA and protein in transfected cells. Next, using an in vitro model, we determined that miR-20a targets the 39-UTR of MICA/B, resulting in diminished NKG2D recognition and subsequently reduced K562 cell killing by NK cells. Finally, we found that miR-20a-mediated downregulation of MICA/B reduces NK cell elimination in vivo by diminishing NKG2D recognition.
Given that MICA/B is not expressed in mice, it is difficult to assess miR-20a-mediated immune evasion in vivo. Recent work by the Pinchas group 21 showed that mouse NK cells could significantly kill human tumor cells via the NKG2D-MICA/B pathway in vivo. Here, we showed that transfection with miR20a resulted in the downregulation of MICA/B on the surface of tumor cells, thus enhancing the survival of tumor cells in vivo. Moreover, we showed that a competitive inhibitor of miR-20a (sponge-miR-20a) significantly cleared tumor cells in vivo. Furthermore, the survival difference observed in various tumor cells in the mouse lung could be eliminated by blocking anti-NKG2D mAb.
In conclusion, we determined that miR-20a targets MICA/B to avoid NKG2D-mediated immune attack and that the upregulation of miR-20a in ovarian cancer reduces MICA/B expression through interaction with its 39-UTR. This desensitizes tumor cells expressing low levels of MICA/B to NK/T-cell killing. Taken together, these data indicate a new role for miR-20a in tumor development and provide novel insights into MICA/B modulation during cancer immune surveillance. 
